A detailed history of Man Group PLC transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Man Group PLC holds 99,371 shares of AUPH stock, worth $892,351. This represents 0.0% of its overall portfolio holdings.

Number of Shares
99,371
Holding current value
$892,351
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.32 - $7.33 $528,653 - $728,389
99,371 New
99,371 $728,000
Q3 2021

Nov 15, 2021

SELL
$10.93 - $23.55 $316,784 - $682,549
-28,983 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$10.0 - $14.52 $815,720 - $1.18 Million
-81,572 Reduced 73.78%
28,983 $376,000
Q1 2021

May 17, 2021

SELL
$12.3 - $18.73 $2.49 Million - $3.8 Million
-202,628 Reduced 64.7%
110,555 $1.44 Million
Q4 2020

Feb 16, 2021

SELL
$12.94 - $16.05 $104,425 - $129,523
-8,070 Reduced 2.51%
313,183 $4.33 Million
Q3 2020

Nov 16, 2020

BUY
$13.19 - $16.66 $78,111 - $98,660
5,922 Added 1.88%
321,253 $4.73 Million
Q2 2020

Aug 14, 2020

BUY
$14.12 - $18.33 $3.27 Million - $4.25 Million
231,743 Added 277.24%
315,331 $5.12 Million
Q1 2020

May 15, 2020

BUY
$11.34 - $21.46 $947,887 - $1.79 Million
83,588 New
83,588 $1.21 Million
Q1 2019

May 15, 2019

SELL
$6.06 - $7.64 $126,653 - $159,676
-20,900 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$5.08 - $6.83 $186,944 - $251,344
-36,800 Reduced 63.78%
20,900 $143,000
Q3 2018

Nov 14, 2018

SELL
$5.27 - $6.64 $4,216 - $5,312
-800 Reduced 1.37%
57,700 $383,000
Q2 2018

Aug 14, 2018

BUY
$5.06 - $6.36 $130,041 - $163,452
25,700 Added 78.35%
58,500 $329,000
Q1 2018

May 15, 2018

BUY
$4.85 - $5.99 $159,080 - $196,472
32,800 New
32,800 $170,000

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.27B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.